Bringing the fundamentals into focus…
Back to Kiniksa Pharmaceuticals International, plc
How Kiniksa Pharmaceuticals International, plc stacks up
KNSA · against 1,336 other Healthcare companies
Valuation
40/ 100
Below the middle of the pack.
Ranked #796 of 1,337 · scores higher than 40% of peers
Bars: peers in each 10-point band of the valuation score134 peers with a valuation score of 40–49, including KNSA · Click a bar to see the companies
Why valuation scores 40?
Weighted metrics compared with all Healthcare companies.A mix: stronger free cash flow yield, but weaker EBITDA yield than most Healthcare peers.
- less operating profit (EBITDA) for the company's total value: weaker than 63% of peers. EBITDA yield: 1.5% vs peer median 4.0%
- Earnings yield is close to the peer norm. Earnings yield: 1.0% vs peer median 1.5%
- more free cash flow for the price paid: stronger than 64% of peers. Free cash flow yield: 2.4% vs peer median 0.0%
Metric by metric
Position: dot = KNSA, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | KNSA | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 1,287 reported | 1.1% | 1.5% | 46% | 30% | |
| EBITDA yieldHigher is better · 1,357 reported | 1.5% | 4.2% | 37% | 50% | |
| Free cash flow yieldHigher is better · 711 reported | 2.5% | -1.0% | 64% | 20% | |
| Book yieldHigher is better · 1,306 reported | 9.0% | 37.9% | 13% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around KNSAScores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score